Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof

US12258365B2 · kind B2 · utility

Assignee

• BETA PHARMA, INC. · US

Inventors

• Don Zhang · Princeton, US
• Jirong Peng · Mequon, US
• Michael N. Greco · Lansdale, US
• Michael John Costanzo · Bonney Lake, US
• Michael Alan Green · Easton, US

Key dates

• Filing date: Dec 14, 2019
• Grant date: Mar 25, 2025
• Expiry date: Mar 15, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides [1,2,4]triazolo[4,3-b][1,2,4]triazine, [1,2,4] triazolo[4,3-b]pyridazine, and [1,2,3]triazolo[4,5-b]pyrazine derivatives, and pharmaceutically acceptable salts, solvates or prodrugs thereof, as tyrosine kinase c-MET inhibitors, which are useful as novel anticancer and/or anti-inflammatory agents.